Tetratherix

Tetratherix Current Liabilities

The Current Liabilities of Tetratherix (TTX.AX) as of Oct 23, 2026 is 5.47 M AUD. In the previous year, Current Liabilities was 1.18 M AUD — a change of 365.75% (higher).

Current Liabilities

5.47 MAUD

YoY

365.75%

Last updated:

Current Liabilities of Tetratherix is 2026 5.47 M AUD. Current Liabilities of Tetratherix was 2025 1.18 M AUD. It decreases by 365.75% higher compared to the previous year.

The Tetratherix Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2023
3.31 M AUD
Jan 1, 2024
5.75 M AUD
Jan 1, 2025
1.18 M AUD
Jan 1, 2026
5.47 M AUD
The Tetratherix Current Liabilities history
YEARCurrent LiabilitiesYoY
5.47 MAUD+365.75%
1.18 MAUD-79.57%
5.75 MAUD+73.78%
3.31 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tetratherix Stock analysis

What does Tetratherix do? Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine, creating injectable products that form 3D matrices upon physiological temperature exposure. The company's biomaterial platform uses polymer programming for implantable solutions, with Tegenix and TegenEOS serving as carriers mixed with bone graft materials for dental, oral, and orthopedic applications. TetraDerm products address surgical incision sites to minimize scarring, while Tutelix functions as a spacer to mitigate radiation therapy side effects in prostate cancer. The firm's manufacturing center in Sydney handles cleanroom production of these medical solutions. The company's revenue streams come from selling Tegenix, TegenEOS, TetraDerm, and Tutelix products to healthcare providers, hospitals, and medical device distributors specializing in regenerative medicine. These products target clinical segments including dental procedures, orthopedic surgery, and oncology treatments. Tetratherix's injectable fluid matrix technology differentiates its offerings by enabling tissue integration without causing bodily damage during application, supporting its positioning in the regenerative medicine market. Tegenix and TegenEOS are marketed as complementary solutions for bone graft applications, while TetraDerm focuses on post-surgical scar reduction. Tutelix specifically addresses radiation therapy side effects in prostate cancer patients. The company's manufacturing center in Sydney ensures quality production of these medical products, which are distributed to healthcare professionals across dental, orthopedic, and oncology fields. Tetratherix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tetratherix stock

Current Liabilities of Tetratherix is 5.47 M AUD in 2026.

Current Liabilities of Tetratherix changed from 1.18 M AUD to 5.47 M AUD, representing a 365.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Tetratherix since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Tetratherix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tetratherix

All Key Metrics — Tetratherix